Zebrafish (Danio rerio) embryos as a model for testing proteratogens

Toxicology

Volumn 281, Issue 1-3, 2011, Pages 25-36

  Weigt, Stefan ^a,b   Huebler, Nicole ^a   Strecker, Ruben ^b   Braunbeck, Thomas ^b   Broschard, Thomas H ^a  

^a MERCK KGAA   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Embryotoxic; Metabolic activation; Proteratogen; Teratogenic; Zebrafish

Indexed keywords

AFLATOXIN B1; BENZO[A]PYRENE; CARBAMAZEPINE; CHEMICAL TERATOGEN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; N (2 FLUORENYL)ACETAMIDE; PHENYTOIN; TEGAFUR; THIOTEPA; TRIMETHADIONE;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL PARAMETERS; CONCENTRATION (PARAMETERS); EFFECTIVE CONCENTRATION 50; EMBRYO; EMBRYOTOXICITY; EXPERIMENTAL MODEL; FEMALE; FERTILIZATION; HATCHING; LC 50; MALE; NONHUMAN; PRIORITY JOURNAL; TERATOGENICITY; TERATOGENICITY INDEX; TOXICITY TESTING; ZEBRA FISH;

2-ACETYLAMINOFLUORENE; AFLATOXIN B1; ANIMALS; CARBAMAZEPINE; CINNARIZINE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; IFOSFAMIDE; MUTAGENICITY TESTS; OVUM; PIRACETAM; TEGAFUR; TERATOGENS; THIOTEPA; TRIMETHADIONE; ZEBRAFISH;

DANIO RERIO; MAMMALIA;

EID: 79851510179     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2011.01.004     Document Type: Article

References (141)

1. Ackland S.P., Choi K.E., Ratain M.J., Egorin M.J., Williams S.F., Sinkule J.A., Bitran J.D. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J. Clin. Oncol. 1988, 6:1192-1196.
2. Amsterdam A., Nissen R.M., Sun Z., Swindell E.C., Farrington S., Hopkins N. Identification of 315 genes essential for early zebrafish development. Proc. Natl. Acad. Sci U.S.A. 2004, 101:12792-12797.
3. Amsterdam A. Insertional mutagenesis in zebrafish: genes for development, genes for disease. Brief Funct. Genomic Proteomic 2006, 5:19-23.
4. Antkiewicz D.S., Burns C.G., Carney S.A., Peterson R.E., Heideman W. Heart malformation is an early response to TCDD in embryonic zebrafish. Toxicol. Sci. 2005, 84:368-377.
5. Augustine-Rauch K., Zhang C.X., Panzica-Kelly J.M. In vitro developmental toxicology assays: a review of the state of the science of rodent and zebrafish whole embryo culture and embryonic stem cell assays. Birth Defects Res. C Embryo Today 2010, 90:87-98.
6. Azarbayjani F., Danielsson B.R. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs?. Epilepsia 2002, 43:457-468.
7. Bachmann, J., 2002. Entwicklung und Erprobung eines Teratogenitäts-Screening Testes mit Embryonen des Zebrabärblings Danio rerio. Ph.D. Thesis, Technical University Dresden, Germany.
8. Banhidy F., Lowry R.B., Czeizel A.E. Risk and benefit of drug use during pregnancy. Int. J. Med. Sci. 2005, 2:100-106.
9. Belanger S.E., Balon E.K., Rawlings J.M. Saltatory ontogeny of fishes and sensitive early life stages for ecotoxicology tests. Aquat. Toxicol. 2010, 97:88-95.
10. Bertilsson L., Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin. Pharmacokinet. 1986, 11:177-198.
11. Brannen K.C., Panzica-Kelly J.M., Danberry T.L., Augustine-Rauch K.A. Development of a zebrafish embryo teratogenicity assay and quantitative prediction model. Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 89:66-77.
12. Braunbeck T., Boettcher M., Hollert H., Kosmehl T., Lammer E., Leist E., Rudolf M., Seitz N. Towards an alternative for the acute fish LC(50) test in chemical assessment: the fish embryo toxicity test goes multi-species-an update. ALTEX 2005, 22:87-102.
13. Brown L.A., Khousbouei H., Goodwin J.S., Irvin-Wilson C.V., Ramesh A., Sheng L., McCallister M.M., Jiang G.C., Aschner M., Hood D.B. Down-regulation of early ionotrophic glutamate receptor subunit developmental expression as a mechanism for observed plasticity deficits following gestational exposure to benzo(a)pyrene. Neurotoxicology 2007, 28:965-978.
14. Brown N.A., Shull G., Fabro S. Assessment of the teratogenic potential of trimethadione in the CD-1 mouse. Toxicol. Appl. Pharmacol. 1979, 51:59-71.
15. Buening M.K., Wislocki P.G., Levin W., Yagi H., Thakker D.R., Akagi H., Koreeda M., Jerina D.M., Conney A.H. Tumorigenicity of the optical enantiomers of the diastereomeric benzo[a]pyrene 7,8-diol-9,10-epoxides in newborn mice: exceptional activity of (+)-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:5358-5361.
16. Bus J.S., Gibson J.E., Reinke D.A. Teratogenicity and neonatal toxicity of ifosfamide in mice. Proc. Soc. Exp. Biol. Med. 1973, 143:965-970.
17. Busquet F., Nagel R., von Landenberg F., Mueller S.O., Huebler N., Broschard T.H. Development of a new screening assay to identify proteratogenic substances using zebrafish Danio rerio embryo combined with an exogenous mammalian metabolic activation system (mDarT). Toxicol. Sci. 2008, 104:177-188.
18. Chakraborty C., Hsu C.H., Wen Z.H., Lin C.S., Agoramoorthy G. Zebrafish: a complete animal model for in vivo drug discovery and development. Curr. Drug Metab. 2009, 10:116-124.
19. Cicurel L., Schmid B.P. Postimplantation embryo culture for the assessment of the teratogenic potential and potency of compounds. Experientia 1988, 44:833-840.
20. de Jonge M.E., Huitema A.D., Rodenhuis S., Beijnen J.H. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 2005, 44:1135-1164.
21. De Vries H.R., Maxwell S.M., Hendrickse R.G. Foetal and neonatal exposure to aflatoxins. Acta Paediatr. Scand. 1989, 78:373-378.
22. Diav-Citrin O., Shechtman S., Arnon J., Ornoy A. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001, 57:321-324.
23. Dirven H.A., van Ommen B., van Bladeren P.J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994, 54:6215-6220.
24. Dirven H.A., Megens L., Oudshoorn M.J., Dingemanse M.A., van Ommen B., van Bladeren P.J. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol. 1995, 8:979-986.
25. Dirven H.A., van Ommen B., van Bladeren P.J. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem. Res. Toxicol. 1996, 9:351-360.
26. Edeki T.I., Brase D.A. Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Drug Metab. Rev. 1995, 27:449-469.
27. Ekhart C., Rodenhuis S., Beijnen J.H., Huitema A.D. Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. Cancer Chemother. Pharmacol. 2009, 63:543-547.
28. Engel D., Nudelman A., Tarasenko N., Levovich I., Makarovsky I., Sochotnikov S., Tarasenko I., Rephaeli A. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties. J. Med. Chem. 2008, 51:314-323.
29. EU (European Union), 2010. Directive 2010/63/EU of the European Parliament and of the Council of the European Union. On the Protection of Animals Used for Scientific Purposes. Official Journal of the European Union. L276, pp. 233-279.
30. Fantel A.G., Greenaway J.C., Juchau M.R., Shepard T.H. Teratogenic bioactivation of cyclophosphamide in vitro. Life Sci. 1979, 25:67-72.
31. Faustman-Watts E.M., Giachelli C.M., Juchau M.R. Carbon monoxide inhibits monooxygenation by the conceptus and embryotoxic effects of proteratogens in vitro. Toxicol. Appl. Pharmacol. 1986, 83:590-595.
32. Finnell R.H., Chernoff G.F. Gene-teratogen interactions: an approach to understanding the metabolic basis of birth defects. Pharmacokinetics in Teratogenesis 1987, 97-109. CRC Press, Boca Raton, Florida. H. Nau, W.J. Scott (Eds.).
33. Fradkin R., Scott W.J., Wilson J.G. Trimethadione teratogenesis in rat and rhesus monkey. Teratology 1981, 24:39A-40A.
34. Fukami T., Nakajima M., Higashi E., Yamanaka H., Sakai H., McLeod H.L., Yokoi T. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab. Dispos. 2005, 33:1202-1210.
35. Gerlinger P., Clavert J. Action of cyclophosphamide injected into pregnant rabbits on the embryonal gonads. C.R. Hebd Seances Acad. Sci. 1964, 258:2899-2901.
36. German J., Kowal A., Ehlers K.H. Trimethadione and human teratogenesis. Teratology 1970, 3:349-362.
37. Gililland J., Weinstein L. The effects of cancer chemotherapeutic agents on the developing fetus. Obstet. Gynecol. Surv. 1983, 38:6-13.
38. Goldstein J.A., Faletto M.B. Advances in mechanisms of activation and deactivation of environmental chemicals. Environ. Health Perspect. 1993, 100:169-176.
39. Griskevicius L., Yasar U., Sandberg M., Hidestrand M., Eliasson E., Tybring G., Hassan M., Dahl M.L. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol. 2003, 59:103-109.
40. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14:611-650.
41. Guengerich F.P. Cytochromes P450, drugs, and diseases. Mol. Interv. 2003, 3:194-204.
42. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8:E101-111.
43. Guengerich F.P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21:70-83.
44. Guryev V., Koudijs M.J., Berezikov E., Johnson S.L., Plasterk R.H., van Eeden F.J., Cuppen E. Genetic variation in the zebrafish. Genome Res. 2006, 16:491-497.
45. Gut I., Danielova V., Holubova J., Soucek P., Kluckova H. Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch. Toxicol. 2000, 74:437-446.
46. Haffter P., Granato M., Brand M., Mullins M.C., Hammerschmidt M., Kane D.A., Odenthal J., van Eeden F.J., Jiang Y.J., Heisenberg C.P., Kelsh R.N., Furutani-Seiki M., Vogelsang E., Beuchle D., Schach U., Fabian C., Nusslein-Volhard C. The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development 1996, 123:1-36.
47. Hales B.F. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein. Cancer Res. 1982, 42:3016-3021.
48. Harbison R.D. Chemical-biological reactions common to teratogenesis and mutagenesis. Environ. Health Perspect. 1978, 24:87-100.
49. Harris C., Stark K.L., Luchtel D.L., Juchau M.R. Abnormal neurulation induced by 7-hydroxy-2-acetylaminofluorene and acetaminophen: evidence for catechol metabolites as proximate dysmorphogens. Toxicol. Appl. Pharmacol. 1989, 101:432-446.
50. Henn K., Braunbeck T. Dechorionation as a tool to improve the fish embryo toxicity test (FET) with the zebrafish (Danio rerio). Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2011, 153:91-98.
51. Hill A.J., Teraoka H., Heideman W., Peterson R.E. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol. Sci. 2005, 86:6-19.
52. A Textbook of Modern Toxicology 2004, John Wiley and Sons, New Jersey. 3rd ed. E. Hodgeson (Ed.).
53. Ikeda K., Yoshisue K., Matsushima E., Nagayama S., Kobayashi K., Tyson C.A., Chiba K., Kawaguchi Y. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin. Cancer Res. 2000, 6:4409-4415.
54. Ioannides C., Cheung Y.L., Wilson J., Lewis D.F., Gray T.J. The mutagenicity and interactions of 2- and 4-(acetylamino)fluorene with cytochrome P450 and the aromatic hydrocarbon receptor may explain the difference in their carcinogenic potency. Chem. Res. Toxicol. 1993, 6:535-541.
55. Ioannides C., Lewis D.F. Cytochromes P450 in the bioactivation of chemicals. Curr. Top. Med. Chem. 2004, 4:1767-1788.
56. Irigaray P., Ogier V., Jacquenet S., Notet V., Sibille P., Mejean L., Bihain B.E., Yen F.T. Benzo[a]pyrene impairs beta-adrenergic stimulation of adipose tissue lipolysis and causes weight gain in mice. A novel molecular mechanism of toxicity for a common food pollutant. FEBS J. 2006, 273:1362-1372.
57. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
58. Jacobson P.A., Green K., Birnbaum A., Remmel R.P. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother. Pharmacol. 2002, 49:461-467.
59. Jain P., Iyer K.R. The cytochrome P450s: versatile biocatalysts. Pharma Times 2004, 36:9-12.
60. 2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. Jpn. J. Clin. Oncol. 2009, 40:29-35.
61. Jiang H., Gelhaus S.L., Mangal D., Harvey R.G., Blair I.A., Penning T.M. Metabolism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid chromatography-mass spectrometry. Chem. Res. Toxicol. 2007, 20:1331-1341.
62. Jones H.S., Panter G.H., Hutchinson T.H., Chipman J.K. Oxidative and conjugative xenobiotic metabolism in zebrafish larvae in vivo. Zebrafish 2010, 7:23-30.
63. Kasapinovic S., McCallum G.P., Wiley M.J., Wells P.G. The peroxynitrite pathway in development: phenytoin and benzo[a]pyrene embryopathies in inducible nitric oxide synthase knockout mice. Free Radic. Biol. Med. 2004, 37:1703-1711.
64. Kerbusch T., Huitema A.D., Ouwerkerk J., Keizer H.J., Mathot R.A., Schellens J.H., Beijnen J.H. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. Br. J. Clin. Pharmacol. 2000, 49:555-561.
65. Kerbusch T., Herben V.M., Jeuken M.J., Ouwerkerk J., Keizer H.J., Beijnen J.H. Distribution of ifosfamide and metabolites between plasma and erythrocytes. Biopharm. Drug Dispos. 2001, 22:99-108.
66. Kerbusch T., Mathot R.A., Keizer H.J., Kaijser G.P., Schellens J.H., Beijnen J.H. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab. Dispos. 2001, 29:967-975.
67. Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., Schilling T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995, 203:253-310.
68. Kishi S., Bayliss P.E., Uchiyama J., Koshimizu E., Qi J., Nanjappa P., Imamura S., Islam A., Neuberg D., Amsterdam A., Roberts T.M. The identification of zebrafish mutants showing alterations in senescence-associated biomarkers. PLoS Genet. 2008, 4:e1000152.
69. Komatsu T., Yamazaki H., Shimada N., Nakajima M., Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos. 2000, 28:1457-1463.
70. Kurata N., Nishimura Y., Iwase M., Fischer N.E., Tang B.K., Inaba T., Yasuhara H. Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica 1998, 28:1041-1047.
71. Lammer E., Carr G.J., Wendler K., Rawlings J.M., Belanger S.E., Braunbeck T. Is the fish embryo toxicity test (FET) with the zebrafish (Danio rerio) a potential alternative for the fish acute toxicity test?. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2009, 149:196-209.
72. Lammer E., Kamp H.G., Hisgen V., Koch M., Reinhard D., Salinas E.R., Wendler K., Zok S., Braunbeck T. Development of a flow-through system for the fish embryo toxicity test (FET) with the zebrafish (Danio rerio). Toxicol. In Vitro. 2009, 23:1436-1442.
73. Lin H.L., Myshkin E., Waskell L., Hollenberg P.F. Peroxynitrite inactivation of human cytochrome P450s 2B6 and 2E1: heme modification and site-specific nitrotyrosine formation. Chem. Res. Toxicol. 2007, 20:1612-1622.
74. Loucks E., Carvan M.J. Strain-dependent effects of developmental ethanol exposure in zebrafish. Neurotoxicol. Teratol. 2004, 26:745-755.
75. McClain R.M., Langhoff L. Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology 1980, 21:371-379.
76. McGrath P., Li C.Q. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov. Today. 2008, 13:394-401.
77. Nagaoka T., Oishi M., Narama I. Reproductive studies of ifosfamide. Kiso to Rinsho 1982, 16:508-568.
78. Nagel R. DarT: the embryo test with the zebrafish Danio rerio-a general model in ecotoxicology and toxicology. ALTEX 2002, 19(Suppl. 1):38-48.
79. Nakamura H., Fujiwara M., Kawasaki M., Nonomura N., Takahashi S. Age-related changes in dividing cells of the olfactory epithelium of the maturing guinea pig. Eur. Arch. Otorhinolaryngol. 1998, 255:289-292.
80. Nau H. Species differences in pharmacokinetics and drug teratogenesis. Environ. Health Perspect. 1986, 70:113-129.
81. Nechiporuk A., Finney J.E., Keating M.T., Johnson S.L. Assessment of polymorphism in zebrafish mapping strains. Genome Res. 1999, 9:1231-1238.
82. Nissen R.M., Amsterdam A., Hopkins N. A zebrafish screen for craniofacial mutants identifies wdr68 as a highly conserved gene required for endothelin-1 expression. BMC Dev. Biol. 2006, 6:28.
83. Novartis Pharmaceuticals, 2000. Product Information. Tegretol.
84. Nulman I., Scolnik D., Chitayat D., Farkas L.D., Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am. J. Med. Genet. 1997, 68:18-24.
85. O'Dougherty M., Wright F.S., Cox S., Walson P. Carbamazepine plasma concentration. Relationship to cognitive impairment. Arch. Neurol. 1987, 44:863-867.
86. OECD (Organization for Economic Cooperation and Development), 2006. OECD Draft Proposal for A New Guideline, 1st Version. Guideline for the Testing of Chemicals. Fish Embryo Toxicity, FET Test.
87. Otte J.C., Schmidt A.D., Hollert H., Braunbeck T. Spatio-temporal development of CYP1 activity in early life-stages of zebrafish (Danio rerio). Aquat. Toxicol. 2010, 100:38-50.
88. Parman T., Chen G., Wells P.G. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J. Biol. Chem. 1998, 273:25079-25088.
89. Parman T., Wells P.G. Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice. FASEB J. 2002, 16:1001-1009.
90. Pearce R.E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. 2002, 30:1170-1179.
91. Pearce R.E., Uetrecht J.P., Leeder J.S. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab. Dispos. 2005, 33:1819-1826.
92. Pearce R.E., Lu W., Wang Y., Uetrecht J.P., Correia M.A., Leeder J.S. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab. Dispos. 2008, 36:1637-1649.
93. Pillai S.P., Menon S.R., Mitscher L.A., Pillai C.A., Shankel D.M. Umbelliferone analogues and their potential to inhibit Benzo(a)pyrene- and hydrogen peroxide-induced mutations. J. Nat. Prod. 1999, 62:1358-1362.
94. Przepiorka D., Madden T., Ippoliti C., Estrov Z., Dimopoulos M. Dosing of thioTEPA for myeloablative therapy. Cancer Chemother. Pharmacol. 1995, 37:155-160.
95. Pugsley M.K., Gallacher D.J., Towart R., Authier S., Curtis M.J. Methods in safety pharmacology in focus. J. Pharmacol. Toxicol. Methods 2008, 58:69-71.
96. Raisuddin S. Toxic responses to aflatoxins in a developing host. J. Toxicol.-Toxin Rev. 1993, 12:175-201.
97. Ramesh A., Greenwood M., Inyang F., Hood D.B. Toxicokinetics of inhaled benzo[a]pyrene: plasma and lung bioavailability. Inhal. Toxicol. 2001, 13:533-555.
98. Redfern W.S., Waldron G., Winter M.J., Butler P., Holbrook M., Wallis R., Valentin J.P. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?. J. Pharmacol. Toxicol. Methods 2008, 58:110-117.
99. Roll R., Matthiaschk G., Korte A. Embryotoxicity and mutagenicity of mycotoxins. J. Environ. Pathol. Toxicol. Oncol. 1990, 10:1-7.
100. Rosemary J., Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr. Clin. Pharmacol. 2007, 2:93-109.
101. Rubinstein A.L. Zebrafish assays for drug toxicity screening. Expert Opin. Drug Metab. Toxicol. 2006, 2:231-240.
102. Sadler K.C., Amsterdam A., Soroka C., Boyer J., Hopkins N. A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development 2005, 132:3561-3572.
103. Schardein J.L., Schwetz B.A., Kenel M.F. Species sensitivities and prediction of teratogenic potential. Environ. Health Perspect. 1985, 61:55-67.
104. Human Developmental Toxicants: Aspects of Toxicology and Chemistry 2007, CRC Press, Boca Raton. 1st ed. J.L. Schardein, O.T. Macina (Eds.).
105. Schmidt R.E., Panciera R.J. Effects of aflatoxin on pregnant hamsters and hamster foetuses. J. Comp. Pathol. 1980, 90:339-347.
106. Scholz S., Fischer S., Gundel U., Kuster E., Luckenbach T., Voelker D. The zebrafish embryo model in environmental risk assessment-applications beyond acute toxicity testing. Environ. Sci. Pollut. Res. Int. 2008, 15:394-404.
107. Selderslaghs I.W., Van Rompay A.R., De Coen W., Witters H.E. Development of a screening assay to identify teratogenic and embryotoxic chemicals using the zebrafish embryo. Reprod. Toxicol. 2009, 28:308-320.
108. Selderslaghs I.W., Hooyberghs J., De Coen W., Witters H.E. Locomotor activity in zebrafish embryos: a new method to assess developmental neurotoxicity. Neurotoxicol. Teratol. 2010, 32:460-471.
109. Seok S.H., Baek M.W., Lee H.Y., Kim D.J., Na Y.R., Noh K.J., Park S.H., Lee H.K., Lee B.H., Park J.H. In vivo alternative testing with zebrafish in ecotoxicology. J. Vet. Sci. 2008, 9:351-357.
110. Shepard T.H., Fantel A.G., Mirkes P.E., Greenaway J.C., Faustman-Watts E., Campbell M., Juchau M.R. Teratology testing: I. Development and status of short-term prescreens. II. Biotransformation of teratogens as studied in whole embryo culture. Prog. Clin. Biol. Res. 1983, 135:147-164.
111. Shepard T.H., Lemire R.J. Catalog of Teratogenic Agents 2004, The Johns Hopkins University Press, Baltimore. 11th ed.
112. Shuaib F.M., Ehiri J., Abdullahi A., Williams J.H., Jolly P.E. Reproductive health effects of aflatoxins: a review of the literature. Reprod. Toxicol. 2010, 29:262-270.
113. Shuey D.L., Setzer R.W., Lau C., Zucker R.M., Elstein K.H., Narotsky M.G., Kavlock R.J., Rogers J.M. Biological modeling of 5-fluorouracil developmental toxicity. Toxicology 1995, 102:207-213.
114. Shum S., Jensen N.M., Nebert D.W. The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism. Teratology 1979, 20:365-376.
115. Sistonen, J., 2008. Pharmacogenetic Variation at CYP2D6, CYP2C9, and CYP2C19: Population Genetic and Forensic Aspects. Ph.D. Thesis, University of Helsinki, Finland.
116. Stark K.L., Harris C., Juchau M.R. Influence of electrophilic character and glutathione depletion on chemical dysmorphogenesis in cultured rat embryos. Biochem. Pharmacol. 1989, 38:2685-2692.
117. Stark K.L., Harris C., Juchau M.R. Modulation of the embryotoxicity and cytotoxicity elicited by 7-hydroxy-2-acetylaminofluorene and acetaminophen via deacetylation. Toxicol. Appl. Pharmacol. 1989, 97:548-560.
118. Stephens J.D., Golbus M.S., Miller T.R., Wilber R.R., Epstein C.J. Multiple congenital anomalies in a fetus exposed to 5-fluorouracil during the first trimester. Am. J. Obstet. Gynecol. 1980, 137:747-749.
119. Streisinger G., Walker C., Dower N., Knauber D., Singer F. Production of clones of homozygous diploid zebra fish (Brachydanio rerio). Nature 1981, 291:293-296.
120. Tanaka E., Ishikawa A., Abei M., Kobayashi S. Trimethadione as a probe drug to estimate hepatic oxidizing capacity in humans. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 1996, 115:211-216.
121. Tanimura T. Relationship of dosage and time of administration to the teratogenic effects of thio-TEPA in mice. Okajimas Folia Anat. Jpn. 1968, 44:203-253.
122. Thompson E.D., Burwinkel K.E., Chava A.K., Notch E.G., Mayer G.D. Activity of phase I and phase II enzymes of the benzo[a]pyrene transformation pathway in zebrafish (Danio rerio) following waterborne exposure to arsenite. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2010, 152:371-378.
123. Ton C., Lin Y., Willett C. Zebrafish as a model for developmental neurotoxicity testing. Birth Defects Res. A Clin. Mol. Teratol. 2006, 76:553-567.
124. Tseng H.P., Hseu T.H., Buhler D.R., Wang W.D., Hu C.H. Constitutive and xenobiotics-induced expression of a novel CYP3A gene from zebrafish larva. Toxicol. Appl. Pharmacol. 2005, 205:247-258.
125. TSO (The Stationary Office), 2000 (revised edition). Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986. London.
126. Valentin J.P., Bialecki R., Ewart L., Hammond T., Leishmann D., Lindgren S., Martinez V., Pollard C., Redfern W., Wallis R. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 2009, 60:152-158.
127. Van Vleet T.R., Mace K., Coulombe R.A. Comparative aflatoxin B(1) activation and cytotoxicity in human bronchial cells expressing cytochromes P450 1A2 and 3A4. Cancer Res. 2002, 62:105-112.
128. Wang-Buhler J.L., Lee S.J., Chung W.G., Stevens J.F., Tseng H.P., Hseu T.H., Hu C.H., Westerfield M., Yang Y.H., Miranda C.L., Buhler D.R. CYP2K6 from zebrafish (Danio rerio): cloning, mapping, developmental/tissue expression, and aflatoxin B1 activation by baculovirus expressed enzyme. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2005, 140:207-219.
129. Wang W.D., Wang Y., Wen H.J., Buhler D.R., Hu C.H. Phenylthiourea as a weak activator of aryl hydrocarbon receptor inhibiting 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 transcription in zebrafish embryo. Biochem. Pharmacol. 2004, 68:63-71.
130. Wangikar P.B., Dwivedi P., Sharma A.K., Sinha N. Effect in rats of simultaneous prenatal exposure to ochratoxin A and aflatoxin B1. II. Histopathological features of teratological anomalies induced in fetuses. Birth Defects Res. B Dev. Reprod. Toxicol. 2004, 71:352-358.
131. Wangikar P.B., Dwivedi P., Sinha N., Sharma A.K., Telang A.G. Teratogenic effects in rabbits of simultaneous exposure to ochratoxin A and aflatoxin B1 with special reference to microscopic effects. Toxicology 2005, 215:37-47.
132. Webster W.S., Brown-Woodman P.D., Ritchie H.E. A review of the contribution of whole embryo culture to the determination of hazard and risk in teratogenicity testing. Int. J. Dev. Biol. 1997, 41:329-335.
133. Weigt S., Huebler N., Braunbeck T., von Landenberg F., Broschard T.H. Zebrafish teratogenicity test with metabolic activation (mDarT): effects of phase I activation of acetaminophen on zebrafish Danio rerio embryos. Toxicology 2010, 275:36-49.
134. Wells P.G., Bhuller Y., Chen C.S., Jeng W., Kasapinovic S., Kennedy J.C., Kim P.M., Laposa R.R., McCallum G.P., Nicol C.J., Parman T., Wiley M.J., Wong A.W. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol. Appl. Pharmacol. 2005, 207:354-366.
135. Westerfield M. The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish, Danio rerio 2000, University of Oregon Press, Eugene. 4th ed.
136. Willett K.L., Gardinali P.R., Lienesch L.A., Di Giulio R.T. Comparative metabolism and excretion of benzo(a)pyrene in 2 species of ictalurid catfish. Toxicol. Sci. 2000, 58:68-76.
137. Wörner W., Schrenk D. Influence of liver tumor promoters on apoptosis in rat hepatocytes induced by 2-acetylaminofluorene, ultraviolet light, or transforming growth factor beta 1. Cancer Res. 1996, 56:1272-1278.
138. Yang L., Ho N.Y., Alshut R., Legradi J., Weiss C., Reischl M., Mikut R., Liebel U., Muller F., Strahle U. Zebrafish embryos as models for embryotoxic and teratological effects of chemicals. Reprod. Toxicol. 2009, 28:245-253.
139. Yerby M.S., Kaplan P., Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin. J. Med. 2004, 71(Suppl. 2):S25-37.
140. Yukiyama S., Shinomiya M., Ikebuchi K., Sato T. Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)-teratological study in rats by oral administration. J. Toxicol. Sci. 1996, 21(Suppl. 3):603-618.
141. Zaliznyak T., Bonala R., Johnson F., de Los Santos C. Structure and stability of duplex DNA containing the 3-(deoxyguanosin-N2-yl)-2-acetylaminofluorene (dG(N2)-AAF) lesion: a bulky adduct that persists in cellular DNA. Chem. Res. Toxicol. 2006, 19:745-752.